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Dr. Beebe’s review eloquently addresses the
issues of levels of evidence and grading of clinical
recommendations.1,2 On the basis of his review, the
current literature on carotid angioplasty and stent-
ing only qualifies for level IV or level V evidence and
grade C clinical recommendations. No higher-qual-
ity level I or level II studies have been conducted,
and therefore no grade A or grade B recommenda-
tions will be available until a well-organized multi-
centered randomized clinical trial that compares the
efficacy of carotid endarterectomy and angioplasty-
stenting is accomplished. A recently published
American Heart Association Science Advisory
emphasized the importance of a future trial stating
that “at this point, with few expectations, use of
carotid stenting should be limited to well designed,
well controlled randomized studies with careful, dis-
passionate oversight.”3
One randomized clinical trial (Carotid and
Vertebral Artery Transluminal Angioplasty Study;
CAVATAS) has been initiated in Great Britain,4 and
another has begun randomization of patients in this
country as sponsored by a major device manufactur-
er.5 However, no clinical results are available. Grant
applications from two other study groups currently
are being considered for funding through the Nation-
al Institutes of Health. Applications from the Carotid
Revascularization Endarterectomy Versus Stent Trial
(CREST) group and from the Carotid Artery Stent
Versus Endarterectomy Trial (CASET) investigators
were reviewed in September 1997 by a Special Em-
phasis Panel, Division of Research Grants at the
National Institutes of Health. Neither group received
a priority score suitable for funding, and a competitive
resubmission is planned for later this year. My impres-
sion is that one of these two studies ultimately will be
funded in this country to address the concerns out-
lined by Dr. Beebe. If a clinical trial is initiated this
year, the results should be available in 2 to 3 years,
and the sooner, the better!
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